- Home
- HAPN vs COAG Comparison
HAPN vs COAG Comparison
Compare HAPN & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAPN | COAG |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2008 | 2026 |
Fundamental Metrics
Financial Performance| Metric | HAPN | COAG |
|---|---|---|
| Price | $14.53 | $34.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $24.50 | ★ $62.67 |
| AVG Volume (30 Days) | ★ 1.6M | 351.8K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $314,702,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.36 | N/A |
| P/E Ratio | $15.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.92 | $27.38 |
| 52 Week High | $21.25 | $55.42 |
Technical Indicators
Market Signals| Indicator | HAPN | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 41.76 |
| Support Level | N/A | $28.46 |
| Resistance Level | $15.68 | $33.93 |
| Average True Range (ATR) | 0.50 | 2.28 |
| MACD | 0.03 | 0.50 |
| Stochastic Oscillator | 30.88 | 60.92 |
Price Performance
Historical ComparisonAbout HAPN Happen Inc. Common Stock
Happen Inc is a U.S. digital marketplace bank focused on the Motivated Middle - high FICO, high-income borrowers actively managing their financial lives. The bank's success is fueled by evolved credit underwriting, a proprietary technology platform, and a marketplace bank model that generates compelling revenue through loan sales, net interest income, and fee-based services.
About COAG Hemab Therapeutics Holdings Inc. Common Stock
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.